NXTC - NextCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

NextCure, Inc.

9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240-399-4900
http://www.nextcure.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees44

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. RichmanCo-Founder, CEO, Pres & DirectorN/AN/A1961
Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/A1957
Mr. Steven P. CobournChief Financial OfficerN/AN/A1963
Dr. Solomon LangermannChief Scientific OfficerN/AN/A1960
Dr. Timothy Mayer Ph.D.Sr. VP of Corp. Devel.N/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.

Corporate Governance

NextCure, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.